Skip to content
10-Q

Quarterly Report

PARATEK PHARMACEUTICALS, INC.

0001564590-21-055249

← back to feed
Filed
Nov 8, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2021 · Oct 29, 2021 50.19M sh
Long Term Debt Q3 2021 · Sep 30, 2021 $253.27M
Long Term Debt Q3 2021 · Dec 31, 2020 $250.47M
Current Liabilities Q3 2021 · Sep 30, 2021 $29.15M
Current Liabilities Q3 2021 · Dec 31, 2020 $23.95M
Total Liabilities Q3 2021 · Sep 30, 2021 $287.34M
Total Liabilities Q3 2021 · Dec 31, 2020 $279.11M
Current Assets Q3 2021 · Sep 30, 2021 $153.01M
Current Assets Q3 2021 · Dec 31, 2020 $164.12M
Total Assets Q3 2021 · Sep 30, 2021 $182.35M
Total Assets Q3 2021 · Dec 31, 2020 $176.85M
Cash And Equivalents Q3 2021 · Dec 31, 2020 $105.16M
Cash And Equivalents Q3 2021 · Sep 30, 2020 $102.36M
Operating Cash Flow Q3 2021 · Sep 30, 2020 −$79.57M
Stockholders Equity Q3 2021 · Sep 30, 2020 −$79.88M
Stockholders Equity Q3 2021 · Jun 30, 2020 −$63.46M
Stockholders Equity Q3 2021 · Mar 31, 2020 −$55.24M
Stockholders Equity Q3 2021 · Dec 31, 2019 −$39.65M
Sga Expense Q3 2021 · Sep 30, 2020 $20.9M
Sga Expense Q3 2021 · Sep 30, 2020 $65.51M
Net Income Q3 2021 · Sep 30, 2020 −$20.86M
Net Income Q3 2021 · Sep 30, 2020 −$71.53M
Net Income Q3 2021 · Jun 30, 2020 −$23.06M
Net Income Q3 2021 · Mar 31, 2020 −$27.62M
Operating Income Q3 2021 · Sep 30, 2020 −$15.95M
Operating Income Q3 2021 · Sep 30, 2020 −$57.97M
Cost Of Revenue Q3 2021 · Sep 30, 2020 $2.02M
Cost Of Revenue Q3 2021 · Sep 30, 2020 $5.72M
Revenue Q3 2021 · Sep 30, 2020 $13.66M
Revenue Q3 2021 · Sep 30, 2020 $30.9M